Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective: pan European patient survey

G Walter Canonica, Ludger Klimek, Sarah Acaster, Ralph Dollner, Ranbir Kaulsay, Siu Hing Lo, David B Price, Glenis K Scadding, Erkka Valovirta, Petra Zieglmayer

Research output: Journal article (peer-reviewed)Journal article

3 Citations (Scopus)


OBJECTIVE: The aims of this survey were to (1) assess the burden of allergic rhinitis (AR) from the patient perspective, (2) investigate MP-AzeFlu use in real life and its impact on patients' lives and (3) explore factors associated with treatment satisfaction.

METHODS: A cross-sectional, quantitative, online, questionnaire-based survey was conducted in seven European countries (March-June 2019). Questions explored AR burden and treatment satisfaction. Satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication 9-item (TSQM-9; max score = 100). Participants (aged ≥18 years) had a doctor/healthcare provider confirmed AR diagnosis and used MP-AzeFlu within the last year.

RESULTS: Pre-MP-AzeFlu treatment, participants (n = 1004) reported an average of 3.3 (SD:3.5) doctor visits/year, 8.1 (SD:11.0) days/year absenteeism and 15.8 (SD:18.9) days/year presenteeism due to AR. Only 48% of participants used MP-AzeFlu twice/day as recommended. Post-MP-AzeFlu 57% of participants reported better QoL, 47% reported fewer doctor visits and 52% discontinued polypharmacy. Absenteeism and presenteeism were reduced by 2.5 (SD 10.0) and 7.3 (SD:16.0) days/year, respectively. 70% of participants were more/much more satisfied with MP-AzeFlu versus previous AR treatment(s), and ≥70% were satisfied/extremely satisfied with its ability to prevent/treat AR, relieve symptoms and with its onset of action. Mean global, effectiveness and convenience TSQM-9 scores were 70.0 (SD:19.8), 68.3 (SD:21.6) and 72.7 (SD:20.4), respectively. Treatment satisfaction and effectiveness were significantly improved when MP-AzeFlu was taken as recommended.

CONCLUSIONS: The impact of AR on patients' lives remains high. Real-life use of MP-AzeFlu reduces that impact and is associated with a high level of effectiveness, convenience and global satisfaction.

Original languageEnglish
Pages (from-to)1259-1272
Number of pages14
JournalCurrent Medical Research and Opinion
Issue number7
Publication statusPublished - Jul 2021


  • Cross-Sectional Studies
  • Fluticasone
  • Humans
  • Phthalazines
  • Quality of Life
  • Rhinitis, Allergic/drug therapy
  • Surveys and Questionnaires


Dive into the research topics of 'Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective: pan European patient survey'. Together they form a unique fingerprint.

Cite this